The FDA heard 80 speakers on the future of psychedelic drugs, and its federal panel asked none of them a question. The American Legion endorsed a VA bill in terms its text doesn’t support, and Alabama showed how one state can stall a federal rescheduling for months.

The post Weekly Psychedelic Policy Briefing, September 21, 2026 appeared first on Psychedelics Today.

Previous articlePα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
Next articleHealth Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity